Introduction {#Sec1}
============

In a subgroup of heart failure patients, treatment by cardiac resynchronisation therapy (CRT) can be beneficial \[[@CR1], [@CR2]\] and is mostly combined with ICD therapy \[[@CR3]\]. Although several studies have confirmed the effect of CRT on improvement in cardiac function, still one-third of patients do not experience noticeable gain from CRT \[[@CR1], [@CR2], [@CR4], [@CR5]\].

To increase the rate of responders, proper timing of pacing pulses may play a role. The proper timing of pacing pulses is of major importance for the created stroke volume and the treatment effect of CRT \[[@CR6], [@CR7]\]. As CRT improves left ventricular function and increases exercise capacity, optimisation of CRT during exercise seems more meaningful than at rest. Since earlier studies show diverse outcomes regarding the optimal timing interval during higher heart rates, with per-individual variation, optimisation of the AV delay should include both measurements at rest and during exercise \[[@CR8]--[@CR12]\].

The gold standard method for general measurement of haemodynamic improvement is invasive \[[@CR13]\]. This technique is too elaborate for routine CRT optimisation and certainly not suitable during exercise. For that reason, non-invasive methods to assess the haemodynamic state have been developed. Echocardiography is widely used but is challenging during exercise.

Recently Van Geldorp et al. \[[@CR14]\] studied the feasibility of a non-invasive method provided by a Nexfin device (Edward Lifesciences BMEYE B.V., Amsterdam, the Netherlands) to continuously monitor beat-to-beat haemodynamics, using a finger cuff. Van Geldorp et al. concluded that this is a promising tool in the individual optimisation of CRT. The Nexfin showed a good performance on the measurement of beat-to-beat stroke volume (SV) changes, the assessment of relative effects induced by CRT and on the determination of the optimal AV delay. The precision of Nexfin in assessing beat-to-beat SV changes was determined at around 6 %, which is considered precise \[[@CR14]--[@CR17]\]. In this study the Nexfin device was used to determine the optimal AV delay during different heart rates during exercise.

In our study the feasibility of a non-invasive finger plethysmographic method (Nexfin, BMEYE B.V., Amsterdam, the Netherlands) in optimisation of atrioventricular delay (AV-delay) during exercise was assessed.

Materials and methods {#Sec2}
=====================

The Nexfin uses the volume-clamp method introduced by Czech physiologist Professor J. Peñaz \[[@CR18]\]. Herein the cuff pressure provides an indirect measure of intra-arterial pressure. To correct the distortion in finger pressure relative to brachial artery pressure, a frequency-dependent filter is used to restore the waveform at the brachial level. The stroke volume is computed by using CO Trek, a model-based method and algorithm which uses a nonlinear, self-adaptive three-element Windkessel model of the aortic input impedance.

All patients known in the Cardiology Department of the Medisch Spectrum Twente implanted with a CRT device in the last 4 years were included according to the inclusion criteria, as shown in Table [1](#Tab1){ref-type="table"}. Using these criteria a patient population was selected in which confounding factors could be largely excluded.Table 1Inclusion criteria- Intact AV conduction.- Patients age \<80 years- CRT implanted on indication of LBBB and according to ESC guidelines- Able to complete a supine bicycle exercise stress protocol- Sinus rhythm, no patients with e.g. permanent atrial fibrillation can be included- No prior valvular surgery.(might alter the physiology of the heart cycle)- CRT in situ for minimally 6 months.(after 6 months the major part of remodelling is assumed to be completed)- No history of irreversible ischaemia in the heart; no previous myocardial infarction or ischaemia present(irreversible ischaemia might have a major influence on heart cycle physiology and the response to CRT)- Posterolateral placement of the left ventricular electrode*CRT* = cardiac resynchronisation therapy, *ESC* = European Society of Cardiology, *LBBB* = left bundle branch block

Test protocol {#Sec3}
-------------

### Preparation {#Sec4}

First, the rate-responsive AV delay of the CRT device is turned off, patients are seated on the exercise bicycle, connected to a 12-lead surface ECG registration system (Philips StressVue, Philips, the Netherlands) and to the Nexfin system using the proper size finger cuff and heart reference system. After application of the measurement devices, some minutes of rest are included to create steady-state conditions in the patient as well as in the measurement devices. The VV delays were not reprogrammed in order to change only one parameter (AV delay) which could influence the haemodynamic circumstances. Most of the patients had a VV delay of −20 or -30 ms.

### Rest protocol {#Sec5}

The optimal AV delay at rest is tested by programming AV delays starting from 40 ms with increments of 20-ms steps, until either intrinsic conductance starts or until a maximum AV delay of 340 ms is reached. When the device can not be programmed in 20-ms steps (St Jude Medical Systems devices when programming AV delays \>200 ms), the test is continued using 25-ms steps. When the VV delay precludes the programming of an AV delay of 40 ms, the first tested AV delay is set to 60 ms or even 80 ms. Prior to each programming step, baseline haemodynamic parameters were collected (10 s averages). Next, the AV delay was reprogrammed and haemodynamic changes compared with baseline were measured, preventing influences of slow haemodynamic changes. Minimally two beats after reprogramming a ten-second averaging of haemodynamic parameters is performed. After this averaging, the AV delay is programmed back to the baseline setting. After a minimum of 25 s, the preparation for the following AV delay setting starts again. After completion of this rest protocol, the optimal rest AV delay is determined as the highest SV increase from baseline to tested AV delay. This is the 'working' optimal AV delay which is used in the exercise protocol that follows. The complete protocol of the study can be found in Appendix [A](#Sec16){ref-type="sec"}.

### Exercise protocol {#Sec6}

The exercise protocol consists of three stages. During the first stage, the target heart rate is set at 15 beats per minute (bpm) above the resting heart rate. In stage two and three, the target heart rate is 30 and 45 bpm higher, respectively, if tolerated by the patient. The patient is instructed to start pedalling at a comfortable cadence of 60 rotations per minute. This cadence is indicated on a screen on the handlebar of the bike. To reach the target heart rate the bicycle's resistance is adjusted. When the target HR is reached, this HR is maintained within 5 bpm from this target rate by adjusting the bicycle's resistance and coaching the patient in the pedalling speed. The AV delays tested during the exercise protocol range from 80 ms shorter than the working optimal AV delay to 80 ms longer. After finishing the first stage, the second and subsequent third stage are performed using the same protocol. The test is ended when stage three has been completed or when the patient becomes too fatigued to continue cycling. (See also the flowchart of the test protocol in Appendix [A](#Sec16){ref-type="sec"}.)

Analysis {#Sec7}
--------

### Optimal AV delay {#Sec8}

Baseline SV, averaged over the 10 s measured before AV delay programming, is subtracted from the averaged SV measured during tested AV delay. As such, the change in SV (∆SV) created by the tested AV delay is found.$$\documentclass[12pt]{minimal}
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Whinnett et al. \[[@CR19]\] demonstrated that the curve of SV response at increasing AV delays fits closely to a second-order polynomial with a maximum. To determine the optimal AV delay we used the least square estimates (LSE) method (Matlab, The Mathworks, USA). This is based on minimisation of the sum of the squared residuals, with a residual being the difference between a measured value and the fitted value provided by the 2nd order polynomial curve.

The point in which the fit over the ΔSV points reaches its maximum is selected as the optimal AV delay for that stage. It is expected that the LSE creates a parabola with a top. When, however, a parabola with a minimum is created or when the calculated maximum is not within reasonably programmable AV delays (\<20 or \> intrinsic guidance) the stage is excluded from further analysis. Per patient the rate dependency of the optimal AV delay in the eligible stages is assessed. The mean change in optimal AV delay in milliseconds per increase in HR in beats per minute is calculated.

### Beneficial effect of optimisation {#Sec9}

The beneficial effect of optimisation is calculated as the percentage of increase in SV potentially to be created by optimisation per stage. Therefore the mean ΔSV corresponding to the minimum of the polynomial fit per stage is subtracted from that corresponding to the maximum. This potential increase is divided by the measured mean SV at the minimum of the fit.

The minimum of the polynomial fit is determined considering reasonably programmable AV delays, the minimum being 40 ms and maximum being 20 ms below AV delay creating intrinsic guidance since in CRT continuous pacing should be preserved.

Results {#Sec10}
=======

Between January 2006 and December 2011, 406 patients received a CRT device. Fifty-three patients met the inclusion criteria. Twenty-two of these patients were not included in the study because of the following reasons: insufficient peripheral circulation to perform the test (*n* = 1), and not willing to perform a cycling test (*n* = 21).

The 25 male and 6 female patients all had a CRT-D device (13 Medtronic, 14 St. Jude, 4 Boston Scientific / Guidant). All patients were receiving adequate ventricular pacing with an average ventricular pacing fraction of 98 %. The mean time after implant was well above 6 months. Therefore it was assumed that cardiac remodelling had ended. See Table [2](#Tab2){ref-type="table"} for further patient characteristics.Table 2Patient characteristicsSexMale25 patientsFemale6 patientsAge65.8 ± 8.9 yearCRT deviceCRT-P0 patientsCRT-D31 patientsDevice brandMedtronic13 patientsSt Jude Medical14 patientsBoston/Guidant4 patientsEF before implant26 ± 7 %Time after implant32.9 ± 14.5 monthsVentricular pacing98 ± 2 %Max stage reachedStage 110 patientsStage 214 patientsStage 37 patients*CRT* = cardiac resynchronisation therapy, *EF* = ejection fraction

Optimal AV delay {#Sec11}
----------------

A total of 90 optimisation stages were performed. For all tested AV delays in these 90 stages the ΔSV was calculated. An example of this for one stage in one patient is shown in Fig. [1](#Fig1){ref-type="fig"}.Fig. 1Optimal AV delay calculation for one stage in one patient. The points mark the ΔSV calculations for the different AV delays. The solid curve is the individual optimisation curve created by the LSE method. The optimal AV delay is selected as the maximum of the optimisation curve (dotted line)

A maximum AV delay could be determined for all tested stages in five patients. In 19 patients there were two or more stages in which a maximum AV delay could be determined. Using the LSE method in 55 (61 %) of the stages a maximum AV delay could be determined. See Table [3](#Tab3){ref-type="table"} for specifications per stage. The mean optimal AV delay was 118 ± 32 ms during rest stages, 121 ± 40 ms during stage 1, 129 ± 30 ms during stage 2 and 109 ± 31 ms during stage 3. The averaged optimal AV delay over all 54 stages was 121 ± 34 ms. See also Table [3](#Tab3){ref-type="table"}.Table 3Percentage of eligible stages and mean optimal atrioventricular (AV) delay per stageOptimal AV delay% with maxMean ± SDRest61 %118 ± 31 msStage 165 %121 ± 40 msStage 257 %129 ± 29 msStage 357 %109 ± 31 msOverall60 %120 ± 34 ms

When considering the optimal AV delay during exercise (in patients with two or more eligible stages), a shortening (1.9 ± 0.9 ms/bpm) of optimal AV delay was found in eight patients (42 %). In four patients (21 %) a lengthening (2.5 ± 1.7 ms/bpm) of optimal AV delay was found. In four patients (21 %) the AV delay did not change with increasing heart frequency, i.e. the optimum stayed within 10 ms. In the remaining three (16 %) patients the optimal AV delay fluctuated with increasing heart frequencies but did not solely shorten or lengthen.

Beneficial effect of optimisation {#Sec12}
---------------------------------

In this study a mean optimisation effect of 10 % was found. In 12 stages a potential increase in stroke volume between 0 and 5 % was observed, in 21 stages an effect between 5 and 10 %. In the resting stages an effect of above 10 % was observed. See also Fig. [2](#Fig2){ref-type="fig"}.Fig. 2Increase in SV created by optimisation

Discussion {#Sec13}
==========

This study was designed to assess the feasibility of Nexfin in optimisation of AV delay during exercise based on SV differences. The Nexfin device was used to determine the effect of HR increase during different levels of exercise on the optimal AV delay. Optimisation of the AV delay resulted in a 10 % potential SV increase. This is a clinically relevant increase indicating that the individual patient could benefit from optimisation by Nexfin during exercise.

The optimal AV delay per stage was determined using Nexfin. Assuming the relation between ΔSV and increasing AV delay can be described by a second order polynomial function, an optimal AV delay could be determined in 61 % of the stages. The other stages showed a fit with a minimum or a fit with a maximum, which was not within reasonably programmable AV delays (\<20 or \> intrinsic guidance).

The mean optimal AV delay found at rest was 118 ms. This indicates that for some patients, the typical default settings (120 ms) can be considered optimal. However, a large standard deviation in optimal AV delay was found. Since it cannot be predicted for whom the out of the box settings will be optimal, this is a strong indication that the AV delay should be optimised individually in every patient with CRT.

In 42 % of the patients eligible for analysis, a shortening in optimal AV delay was found for increasing heart rates, whereas 21 % showed a *lengthening* in optimal AV delay. These results are in accordance with the highly diverse outcomes in earlier studies \[[@CR8]--[@CR12]\]. The use of different methods for measurement of SV has been suggested as a possible explanation for this diversity. Another explanation, which our study supports, could be the patient dependency in rate responsive optimal AV delay.

In currently available CRT devices the AV delay can only be programmed to a fixed rate or to dynamic shortening, while lengthening of the AV delay during CRT is not an option. This study, and the earlier mentioned study by Scharf \[[@CR9]\], indicated a potential benefit of lengthening of the AV delay for a certain patient group. Because of earlier mentioned conflicting evidence on rate adaptive AV delay in the literature, it is currently advised that the rate responsive AV delay should be inactivated by default \[[@CR12], [@CR20]\]. However programming rate responsive AV delay ON was encouraged in the MIRACLE trials \[[@CR5]\]. A recent pilot study by Shanmugam \[[@CR21]\] showed that programming rate adaptive AV delay ON improves exercise capacity and advised to revise the debate regarding rate adaptive AV delay.

Only a few other devices provide continuous and non-invasive stroke volume during exercise. The Finometer (Finapress Medical Systems, Amsterdam, the Netherlands) also uses the volume clamping and a pulse contour analysis method to determine stroke volume. However, this device needs frequent calibration with an upper arm cuff. The Nicom system (Cheetah Medical, Vancouver, USA) uses bioreactance to measure stroke volume. These measurements have been found feasible and reliable for AV delay optimisation. However, this has not yet been tested during exercise where this may be a challenge due to the system's vulnerability to motion artifacts \[[@CR22]\].

Limitations {#Sec14}
===========

The first limitation is that only 6 female patients were included in the study. However, women appear to be generally underrepresented in patients who receive ICDs and CRT devices \[[@CR23]\]. Secondly, the VV delay was deliberately not reprogrammed to assess the effect of changing the AV delay only. Adapting the VV delay as well could have resulted in an even higher increase of SV. And a third limitation is that the study only describes the acute haemodynamic effects; long-term follow-up data will become available next year.

Conclusion {#Sec15}
==========

This study is a first step in clinical application of the Nexfin in AV delay optimisation during exercise. In every patient AV delay at rest and during exercise should be optimised individually. A potential increase in SV of 10 % can be achieved using Nexfin for optimisation of AV delay during exercise while a considerable number of patients showed benefit with *lengthening* of the AV delay during exercise.

Appendix A {#Sec16}
==========
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